# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 91-100 of 574 results.
Lenalidomide Monotherapy in R/R DLBCL
Status: Recruiting
Last Changed: Nov 04, 2019
First Received: Nov 04, 2019
Disease(s): Diffuse Large B Cell Lymphoma
Locations: MorphoSys Research Site, Rochester, Minnesota, United States
MorphoSys Research Site, Saint Louis, Missouri, United States
MorphoSys Research Site, Manhasset, New York, United States
MorphoSys Research Site, New York, New York, United States
MorphoSys Research Site, Rochester, New York, United States
... and 53 other locations.
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Aug 19, 2019
First Received: May 02, 2017
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): ABT-199, Ibrutinib, Rituximab
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Status: Recruiting
Last Changed: Jul 26, 2019
First Received: Oct 17, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Nivolumab, IV, 240 mg
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
Status: Recruiting
Last Changed: Dec 02, 2019
First Received: Oct 22, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tafasitamab, Tafasitamab plus Lenalidomide
Locations: MorphoSys Research Site, Encinitas, California, United States
MorphoSys Research Site, Washington, District of Columbia, United States
MorphoSys Research Site, Washington, District of Columbia, United States
MorphoSys Research Site, Louisville, Kentucky, United States
MorphoSys Research Site, Rochester, Minnesota, United States
... and 34 other locations.
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
Status: Recruiting
Last Changed: Nov 15, 2019
First Received: Aug 21, 2018
Disease(s): B-cell Non-Hodgkin's Lymphoma
Intervention(s): GB226
Locations: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Chidamide With R-CHOP Regimen for DLBCL Patients
Status: Recruiting
Last Changed: Aug 02, 2018
First Received: Jun 28, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Chidamide + R-CHOP regimen
Locations: The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Recruiting
Last Changed: Apr 19, 2019
First Received: Aug 28, 2017
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Enzastaurin Hydrochloride, R-CHOP + placebo
Locations: Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States
Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States
Centura Health Corporation, Denver, Colorado, United States
Christiana Care Health Services, Inc, Newark, Delaware, United States
Loyola University Medical Center, Maywood, Illinois, United States
... and 50 other locations.
A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Status: Recruiting
Last Changed: Nov 18, 2019
First Received: Aug 05, 2016
Disease(s): Mature B-cell Neoplasms
Intervention(s): HMPL-523
Locations: BeijingCancer Hospital, Beijing, Beijing, China
Fudan University Shanghai Cancer Hospital, Shanghai, China
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Nov 28, 2019
First Received: Sep 14, 2018
Disease(s): B-cell Non-Hodgkin Lymphoma
Intervention(s): Mosunetuzumab, Polatuzumab vedotin, Rituximab, Bendamustine, Tocilizumab
Locations: University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
University of Miami Miller School of Medicine, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
... and 8 other locations.
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Nov 20, 2019
First Received: Nov 20, 2019
Disease(s): Relapsed and Refractory B Cell Lymphoma, Non-Hodgkin Lymphoma
Intervention(s): CD20 CAR-T
Locations: The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China